Glioma
|
0.400 |
Biomarker
|
disease |
LHGDN |
Rottlerin sensitizes glioma cells to TRAIL-induced apoptosis by inhibition of Cdc2 and the subsequent downregulation of survivin and XIAP.
|
15531913 |
2005 |
Glioma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Weak expression of DR5 in primary glioma might limit the therapeutic application of Apo2L/TRAIL in human glioblastoma patients.
|
17595512 |
2007 |
Glioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Enhanced apoptosis of glioma cell lines is achieved by co-delivering FasL-GFP and TRAIL with a complex Ad5 vector.
|
14605667 |
2003 |
Glioma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Finally, MSCs expressing TRAIL improved the median survival of irradiated mice bearing intracranial U87 glioma xenografts in comparison with nonirradiated and irradiated control mice.
|
24002694 |
2014 |
Glioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
An Integrated Stress Response Agent that Modulates DR5-Dependent TRAIL Synergy Reduces Patient-Derived Glioma Stem Cell Viability.
|
30642878 |
2019 |
Glioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Moreover, Ad-Apo2L/TRAIL gene transfer inhibits soluble His-tagged Apo2L/TRAIL-induced apoptosis, strongly suggesting that the adenovirally encoded full-length Apo2L/TRAIL is not a suitable molecule for glioma cancer gene therapy.
|
12587790 |
2003 |
Glioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
These PEI-PLL-transfected mesenchymal stem cells with HSV-TK and TRAIL genes have the potential to treat glioma both in vitro and in vivo.
|
30223091 |
2018 |
Glioma
|
0.400 |
Biomarker
|
disease |
LHGDN |
A novel p53 rescue compound induces p53-dependent growth arrest and sensitises glioma cells to Apo2L/TRAIL-induced apoptosis.
|
18202704 |
2008 |
Glioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Human glioma organotypic slices treated with AdsTRAIL demonstrated apoptosis induction and caspase activation.
|
21368892 |
2011 |
Glioma
|
0.400 |
AlteredExpression
|
disease |
LHGDN |
Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo.
|
12118245 |
2002 |
Glioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The effect of NP-TRAIL was examined on the apoptosis of glioma cells and self-renewal of glioma stem cells (GSCs).
|
23144078 |
2013 |
Glioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Since PKCε has been implicated in the resistance of glioma cells to TRAIL, we examined its role in TRAIL and proteasome inhibitor-induced apoptosis.
|
21440622 |
2011 |
Glioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Inhibition of either PPARgamma or MEK1/2 blocked the Troglitazone-mediated phosphorylation of BAD and further increased the synergistic induction of glioma cell death by TRAIL and Troglitazone.
|
19158480 |
2008 |
Glioma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
It also sensitizes human glioma cells against TRAIL by increasing DR5 expression.
|
21392090 |
2011 |
Glioma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We analyzed the expression of TRAIL and its receptors in a panel of human brain tumors (n = 34) and in four glioma cell lines in comparison to normal brain tissue.
|
10198234 |
1999 |
Glioma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The authors first examined sensitivity to TRAIL and expression of TRAIL receptors in four established and four primary cultured glioma cell lines by using viability and fluorescent apoptosis assays.
|
15844877 |
2002 |
Glioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We thus established the TRAIL resistance models on glioma by using the U87 and U251 cell lines (U87/R and U251/R).
|
31056533 |
2019 |
Glioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Digitoxin increases sensitivity of glioma stem cells to TRAIL-mediated apoptosis.
|
28511914 |
2017 |
Glioma
|
0.400 |
Biomarker
|
disease |
LHGDN |
Novel therapeutic approaches using TRAIL or agonistic TRAIL receptor antibodies in combination with proteasome inhibitors may represent a promising approach to reactivate apoptosis in therapy-resistant high-grade gliomas.
|
18341587 |
2008 |
Glioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We found that osthole and TRAIL alone, had no effect on apoptosis, but combined treatment with osthole and TRAIL markedly induced apoptosis in Caki (renal carcinoma), U251MG (glioma) and MDA-MB-231 (breast carcinoma) cells.
|
28350076 |
2017 |
Glioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Taken together, these findings suggest that resistance to TRAIL by lack of TRAIL receptors on glioma is restored by genotoxic agents, which support the new strategies for tumour killing by TRAIL-bearing cytotoxic cells in combination with genotoxic treatment.
|
12610517 |
2003 |
Glioma
|
0.400 |
Biomarker
|
disease |
LHGDN |
Roles of tyrosine phosphorylation and cleavage of protein kinase Cdelta in its protective effect against tumor necrosis factor-related apoptosis inducing ligand-induced apoptosis.
|
15774464 |
2005 |
Glioma
|
0.400 |
Biomarker
|
disease |
LHGDN |
Real-time imaging of TRAIL-induced apoptosis of glioma tumors in vivo.
|
14534533 |
2003 |
Glioma
|
0.400 |
Therapeutic
|
disease |
CTD_human |
Possible novel therapy for malignant gliomas with secretable trimeric TRAIL.
|
19229339 |
2009 |
Glioma
|
0.400 |
Therapeutic
|
disease |
CTD_human |
The results of the present study show that the anti-diabetic drug troglitazone sensitizes human glioma and neuroblastoma cells to TRAIL-induced apoptosis.
|
16820965 |
2006 |